MannKind Stock (NASDAQ:MNKD)
Previous Close
$6.86
52W Range
$3.17 - $7.63
50D Avg
$6.67
200D Avg
$5.27
Market Cap
$1.89B
Avg Vol (3M)
$2.50M
Beta
1.30
Div Yield
-
MNKD Company Profile
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MNKD Performance
Peer Comparison
| Ticker | Company |
|---|---|
| KNSA | Kiniksa Pharmaceuticals, Ltd. |
| BMRN | BioMarin Pharmaceutical Inc. |
| SGMO | Sangamo Therapeutics, Inc. |
| UTHR | United Therapeutics Corporation |
| TECH | Bio-Techne Corporation |
| ADAP | Adaptimmune Therapeutics plc |
| AFMD | Affimed N.V. |
| VSTM | Verastem, Inc. |
| IMMP | Immutep Limited |
| ACER | Acer Therapeutics Inc. |
| LQDA | Liquidia Corporation |
| LEGN | Legend Biotech Corporation |